

Molecular pathology of acute respiratory distress syndrome, mechanical ventilation and abnormal coagulation in severe COVID-19

Antoine Soulé^{1,*}, William Ma^{1,*}, Katelyn Yixiu Liu², Catherine Allard³, Salman Qureshi², Karine Tremblay^{4,†}, Amin Emad^{1,5,†} and Simon Rousseau^{2,†}

* These authors contributed equally.

¹ Department of Electrical and Computer Engineering, McGill University, Montréal, QC, Canada

² The Meakins-Christie Laboratories at the Research Institute of the McGill University Health Centre Research Institute, & Department of Medicine, Faculty of Medicine, McGill University, Montréal, QC, Canada

³ Statistical department, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS), Sherbrooke, Canada.

⁴ Pharmacology-physiology Department, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Saguenay, QC, Canada; Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean, Saguenay, QC, Canada; CRCHUS, Sherbrooke, Canada.

⁵ Mila, Quebec AI Institute, Montréal, QC, Canada

† Co-corresponding Authors:

Simon Rousseau,
RI-MUHC, E M3.2244, 1001 Décarie, Montréal H4A 3J1, Canada,
Email: simon.rousseau@mcgill.ca

Amin Emad,
755 McConnell Engineering Building, 3480 University Street, Montreal H3A 0E9, Canada
Email: amin.emad@mcgill.ca

Karine Tremblay,
Pavillon des Augustines, local AUG-5-01A, 225 St-Vallier street, Chicoutimi G7H 7P2, Canada
Email: karine.tremblay@usherbrooke.ca

1 **Abstract**

2 Systemic inflammation in critically ill patients can lead to serious consequences such as acute
3 respiratory distress syndrome (ARDS), a condition characterized by the presence of lung
4 inflammation, edema, and impaired gas exchange, associated with poor survival. Understanding
5 molecular pathobiology is essential to improve critical care of these patients. To this end, we use
6 multimodal profiles of SARS-CoV-2 infected hospitalized participants to the Biobanque
7 Québécoise de la COVID-19 (BQC-19) to characterize endophenotypes associated with different
8 degrees of disease severity. Proteomic, metabolomic, and genomic characterization supported a
9 role for neutrophil-associated procoagulant activity in severe COVID-19 ARDS that is inversely
10 correlated with sphingosine-1 phosphate plasma levels. Fibroblast Growth Factor Receptor
11 (FGFR) and SH2-containing transforming protein 4 (SHC4) signaling were identified as molecular
12 features associated with endophenotype 6 (EP6). Mechanical ventilation in EP6 was associated
13 with alterations in lipoprotein metabolism. These findings help define the molecular mechanisms
14 related to specific severe outcomes, that can be used to identify early unfavorable clinical
15 trajectories and treatable traits to improve the survival of critically ill patients.

16

17 **Introduction**

18 Acute respiratory distress syndrome (ARDS), a condition characterized by the presence of lung
19 inflammation, edema, and impaired gas exchange, is observed in severe coronavirus disease
20 2019 (COVID-19) and associated with poor survival. Mechanical ventilation is an important critical
21 care management strategy for severe COVID-19 (1). However, during the first waves of the
22 pandemic, almost half of patients undergoing invasive mechanical ventilation died based on case
23 fatality rate reports (2). Defining the molecular mechanisms related to specific severe outcomes,
24 such as ARDS or acute respiratory failure that require invasive mechanical ventilation, is
25 important to identify treatable traits and improve the survival of critically ill patients.

26

27 Endophenotypes are subgroups which are inapparent to traditional methods but share a
28 common set of factors that dictate their response in a manner that is distinct from other sub-
29 groups (3). Endophenotypes have been described in airway diseases such as asthma (4), COPD,
30 (5) and chronic rhinosinusitis (6). Recent studies have identified endophenotypes associated with
31 COVID-19 severity using different large data sets, such as bulk transcriptomic from blood (7), bulk
32 transcriptomic from neutrophil-enriched fractions (8), or proteomic in our accompanying
33 manuscript (9).

34

35 In this manuscript, we report multimodal characterization of one of the six endophenotypes (EPs)
36 identified in our accompanying manuscript (9), which we found to be associated with the worst
37 clinical trajectory during hospitalization following SARS-CoV-2 infection (including ARDS). This

38 analysis reveals known and novel molecular effectors of immuno-thrombosis, ARDS and
39 mechanical ventilation associated with COVID-19.

40

41 **Results**

42 **Serprocidins are enriched in an endophenotype associated with COVID-19 severity and ARDS**

43 To gain insight into the molecular mechanisms underlying the severity in COVID-19, we
44 investigated the aptamers enriched within an endophenotype (EP6) (Figure 1 and Table S1) that
45 we previously discovered using the circulating proteome of SARS-CoV-2 infected and hospitalized
46 participants to BQC19 (n = 731) and found to be associated with severe outcome and ARDS (9).
47 These aptamers correspond to measurements obtained using a multiplex SOMAmer affinity
48 array. We used two-sided Mann–Whitney U (MWU) tests and the p-values were corrected for
49 the number of aptamers and EPs using Benjamini–Hochberg (BH) false discovery rate (FDR).
50 Consistent with the elevated neutrophil numbers in EP6, the most enriched aptamer was
51 Cathepsin G (FDR = 4.10E-58), a serine protease localized in neutrophil azurophil granules.
52 Notably, two other serprocidins, neutrophil elastase and proteinase-3, were also significantly
53 enriched in EP6 (FDR = 1.04E-10 and FDR = 8.27E-7, respectively, Figure 1 and Table S1).
54 Moreover, another NETosis-associated protein, Olfactomedin 4 (OLFM4) (10), was greatly
55 enriched in EP6 (top 5%; FDR = 2.61E-46, Figure 1 and Table S1). This suggests an important role
56 for neutrophil degranulation and/or NETosis in severe COVID-19.

57

58 **Pathway enrichment analysis identified FGFR-signaling in severe COVID-19 acute respiratory**
59 **distress syndrome**

60 To capture a more comprehensive landscape of the signaling networks active in EP6, we
61 performed pathway enrichment analysis using the Knowledge Engine for Genomics (KnowEnG)
62 (11). Since aptamers were used to identify the EPs, it is expected that many of them would have
63 significant associations with the EPs. As a result, we selected a very strict threshold of FDR < 1E-
64 20 (two-sided MWU test, BH FDR) to identify top aptamers associated with EP6 (9). We then used
65 the gene set characterization pipeline of KnowEnG with Reactome pathway collection (12). This
66 analysis showed that EP6 is characterized by pathways associated with interleukins and cytokine
67 signaling in the immune system. In addition, fibroblast growth factor receptor (FGFR) signaling
68 was identified in EP6, suggesting this pathway as a potential driver of severe pathology (Table 1
69 and S1).

70

71 **EP6 metabolomic signature was associated with pro-coagulant activities and liver dysfunction**

72 To further characterize the pathobiology of severe COVID-19 disease, metabolomic profiling of
73 plasma samples was performed in parallel to the aptamer analysis. The results yielded data on
74 1,435 metabolites, of which 576 were found significantly altered in EP6 (two-sided MWU FDR <
75 0.01) (Table S2). Characterization of the plasma samples supported the distinction among the
76 different EPs at the levels of metabolomic sub-pathways and individual metabolites (Figure 2 and
77 Table S2). The two top sub-pathways (FDR < 0.01) “Methionine, Cysteine, SAM and Taurine
78 Metabolism” and “phosphatidylethanolamine (PE)”, are known to interact (13, 14) and are
79 associated with pro-coagulant activities. Phospholipids-containing microparticles from platelet
80 activation contribute to Tissue Factor activation and pro-thrombinase activity (15), linking PE to
81 coagulation and D-dimers level, which are elevated in EP6 (9). PE methylation acts as a major

82 consumer of S-Adenosylmethionine (SAM) leading to the synthesis of S-Adenosylhomocysteine
83 (SAH) and cystathionine (14), upstream of 2-hydroxybutyrate and 2-aminobutyrate in a model of
84 hepatotoxicity (16). SAH, cystathionine, 2-hydroxybutyrate and 2-aminobutyrate are all
85 significantly enriched in EP6 (Figure 2B and 3A). To identify relationships that may shed light on
86 factors influencing clinical laboratory results that define EP6, we also performed Spearman's rank
87 correlation analyses between 21 blood variables and metabolites (Table S3). SAH is positively
88 correlated with creatinine, while cystathionine is positively correlated with creatinine and
89 negatively correlated with albumin (Figures 4, S1-S2), congruent with the data from the model of
90 hepatotoxicity (16), linking abnormal coagulation and liver damage in severe COVID-19. We also
91 observed kynurenine to be enriched in EP6 but depleted in EP1 (Figures 3 and 5). Kynurenine
92 levels were also found to be positively correlated with D-Dimers levels (Figure 4 and S1-S2),
93 suggesting a role of this metabolite of the tryptophan pathway in abnormal coagulation in severe
94 COVID-19. Interestingly, TNFSF18 (GITR), a T-cell receptor that can activate indoleamine 2,3-
95 dioxygenase (IDO) to increase kynurenine synthesis (17) in allergy, is enriched in EP6 and
96 depleted in EP1 (Figures 3 and 5).

97

98 **Low levels of sphingosine-1 phosphate are associated with COVID-19 ARDS**

99 Strikingly, sphingosine-1 phosphate was enriched in EP1 and depleted in EP6 (Figures 3 and 5),
100 confirming the previously reported negative association of this metabolite with COVID-19 ARDS
101 (18). Accordingly, the aptamer detecting neutral ceramidase, an enzyme converting ceramides
102 into sphingosine, is enriched in EP1 (FDR = 2.65E-10, Table S1). While changes in protein
103 abundance as detected by aptamers may not necessarily reflect changes in enzymatic activity, it

104 is interesting to note that dihydroceramides and ceramides are depleted in EP1 (Figure 5, Table
105 S1). Conversely, dihydroceramides and ceramides are significantly enriched in EP6 (Figure 3,
106 Table S1). Moreover, one of the top aptamers found enriched in EP6 (FDR = 2.10E-56, Figure 1)
107 is serine palmitoyltransferase 2 (SPTLC2), an enzyme that is responsible for the rate-limiting step
108 in *de novo* sphingolipid biosynthesis (19, 20).

109

110 **Mechanical ventilation in EP6 is associated with lipoprotein metabolism**

111 As noted in the introduction, mechanical ventilation in COVID-19 is associated with a high
112 mortality rate. Within EP6, 55 out of the 118 individuals received mechanical ventilation. Within
113 all EP6 members that share the overall similar aptamer signature, we identified a subset of
114 aptamers and metabolites that were significantly different between those with or without
115 mechanical ventilation (Figure 6A and Table S4). The second most enriched aptamer (Table 2 and
116 S4), angiotensin-like 3 (ANGPTL3), corresponds to a liver-secreted regulator of lipoprotein
117 metabolism (21), which may reflect alterations observed in fatty acid metabolites (Table S4).
118 There were no significant differences between the two groups in terms of sex, age, or body mass
119 index (BMI) (Figure 6B-6C and Table S4). Finally, we investigated whether molecular information
120 (proteomic and/or metabolomic) was associated with mechanical ventilation duration. We
121 identified alpha-L-iduronidase (IDUA) to be inversely correlated with duration of ventilation in
122 the patients with mechanical ventilation in EP6 (Spearman's rank correlation = -0.60, FDR = 2.57E-
123 2, Figure 6D and Table S4). Overall, these results point to an association between altered
124 lipoprotein metabolism and mechanical ventilation in EP6.

125

126 **SHC4 genotype and protein expression levels are associated with higher odds of belonging to**

127 **EP6**

128 To obtain independent support for the involvement of specific proteins identified using
129 aptamers, we leveraged genome-wide association study (GWAS) genotyping data corresponding
130 to these patients. We identified 25 single nucleotide variations (SNVs) distributed in 13 annotated
131 genes that were below a p-value threshold of 1E-4 and distinguished EP6 from the rest (Table 3).
132 We then investigated each of the SNVs to which we could assign a gene and an aptamer, to assess
133 whether their protein product in circulation was differentially regulated by the genotype (Table
134 4). We discovered two genes, *SHC4* (encoding SHC adaptor protein 4) and *CACNA2D3* (encoding
135 calcium voltage-gated channel auxiliary subunit alpha2 delta3) for which there was a significant
136 association between genotype and protein expression levels (p-values < 0.05). While *CACNA2D3*
137 may have mild impact on EP6 membership (odds ratio = 0.61, Table 4), *SHC4* was one of the top-
138 enriched aptamers (position 32 out of 4,985, Figure 1) for inclusion in EP6, with an odds ratio of
139 11.98 for the protein product and 2.00 for the alternate allele, respectively. Finally, to gain further
140 insight into the potential role of *SHC4* in COVID-19 disease severity, we investigated the
141 metabolites associated with *SHC4* in EP6. The only significantly correlated metabolite was 6-
142 oxopiperidine-2-carboxylate (Spearman's rank correlation = 0.40, FDR = 0.012, Figures 4, S1-S2),
143 where the p-values were corrected for the number of metabolites using BH FDR. Therefore, the
144 GWAS analysis revealed that the signaling adaptor protein *SHC4* may play an important
145 mechanistic role in contributing to severe disease pathology.

146

147 **Discussion**

148 In this study, we leveraged the molecular features associated with endophenotypes discovered
149 using unsupervised hierarchical clustering of circulating proteome of SARS-CoV-2 positive
150 hospitalized participants to BQC19 to improve our understanding of pathobiology. This approach
151 enabled the identification of the following molecular features: 1) the level of Sphingosine-1
152 phosphate is highest in EP1 and lowest in EP6, reflecting an inverse association with time to
153 admission to ICU and/or death; 2) interleukins and FGFR signaling are molecular pathways
154 associated with severe COVID-19; 3) genetic and environmental determinants of SHC4 expression
155 are associated with inclusion in EP6; 4) the combined proteomic and metabolomic signature of
156 EP6 supports a pathologic role for neutrophil-associated procoagulant activity in COVID-19 ARDS;
157 and 5) mechanical ventilation in EP6 is associated with altered lipoprotein metabolism.

158

159 *COVID-19 ARDS molecular pathology: a counterbalance between ceramides and sphingosine is*
160 *associated with critical illness.*

161 The datasets used in this study carry rich molecular information on mechanisms of disease for
162 COVID-19. EP6 is characterized by its enrichment in ARDS (50% vs 9% in EP1), acute kidney injury
163 (50%) and liver dysfunction (22%) (9). Low levels of Sphingosine 1-phosphate (S1P) are associated
164 with ARDS and have been shown to be associated with greater ICU admission and decreased
165 survival in COVID-19 (18), and is supported by this study where S1P levels were found depleted
166 in EP6 but enriched in EP1 (the endophenotype with the best prognostic). The study also supports
167 a shunting away from sphingosine towards more pro-inflammatory ceramides that are associated
168 with metabolic disorders (22), suggesting a counterbalance between ceramides and sphingosine,

169 where the former is associated with poorer outcomes during critical illness, whereas higher levels
170 of the latter is associated with more favorable outcomes in ARDS.

171

172 *Molecular mechanisms of mechanical ventilation in EP6: a potential role for ANGPTL3*

173 ANGPTL3 is a liver-secreted enzyme that can inhibit lipoprotein and endothelial lipase (23). Loss-
174 of-function of ANGPTL3 is associated with hypolipidemia (24). Therefore, increased circulating
175 levels of ANGPTL3 would be expected to raise plasma levels of triglycerides and phospholipids
176 which is consistent with the observed metabolomic profiles (Table S4). Whether these alterations
177 are sufficient to increase the likelihood of mechanical ventilation remains speculative.
178 Nevertheless, it is interesting to note that administration of medium- and long-chain triglycerides
179 can aggravate gas exchange abnormalities in ARDS (25) and may warrant the preclinical
180 investigation of ANGPTL3 antagonists like evinacumab or other functionally similar therapeutic
181 agents (26) in ameliorating outcomes in ARDS. As for the duration of mechanical ventilation, we
182 discovered an inverse correlation with IDUA, a lysosomal enzyme required for the degradation
183 of heparan sulfate and dermatan sulfate (27). Our current data cannot distinguish between the
184 presence of this enzyme as a biomarker or as an active mediator that influences the course of
185 COVID-19-associated acute respiratory failure.

186

187 *Multimodal profiling of EP6 supports a role for neutrophil-derived procoagulant activity-mediated*
188 *organ damage in COVID-19.*

189 COVID-19 ARDS has been found to be more frequently associated with thrombotic complications
190 than non-COVID-19 ARDS (28, 29). In addition, histopathologic evidence of pulmonary

191 microthrombi is frequently observed in autopsies of individuals deceased with COVID-19 (30).
192 Early reports suggested a role for neutrophil-mediated release of NETs contributing to
193 endothelial dysfunction as a mechanism of microthrombosis in COVID-19 ARDS (31-42). The
194 neutrophil-derived serprocidins cathepsin G, neutrophil elastase, and proteinase-3, are
195 significantly enriched in EP6. In addition to their roles in bacterial killing, serprocidins couple
196 innate immunity to coagulation, where they promote coagulation by enhancing tissue factor and
197 factor XII-dependent coagulation (43). Serprocidins are also important regulators of NETosis (44).
198 In pediatric sepsis, another NETosis-associated protein olfactomedin 4 (OLFM4) (10), enriched in
199 EP6, is associated with increased odds of having greater organ failure and death (45). The
200 procoagulant environment associated with COVID-19-associated organ damage is further
201 supported by the alteration in metabolic profiles in EP6. Phosphatidylethanolamines (PE)
202 become exposed at the surface of cell membranes upon exposure to stress, inflammation, and
203 cell death (46, 47). In a Syrian hamster model, infection with SARS-CoV-2 markedly increased
204 circulating PE expression in the animals that were fed a high salt, high fat diet, demonstrating the
205 interaction between infection and metabolic disorder (48). Furthermore, the membranes of
206 azurophilic granules, which contain serprocidins, are enriched in PE (49). Accordingly, EP6 is
207 associated with decreased platelet counts, increased D-Dimers, international normalized ratio
208 (INR) and activated partial thromboplastin time (aPTT) (9), hallmarks of abnormally activated
209 coagulation pathways that are associated with serious and often lethal complication of sepsis
210 (50). Accordingly, we report an association between kynurenine and D-dimer, pointing to an
211 involvement of tryptophan metabolism in abnormal coagulation. Interestingly, TNFSF18, a T-cell
212 receptor that promotes leukocyte adhesion to endothelial cells (51), is enriched in EP6. A SNV

213 found in the proximity of TNFSF18 was found associated with severity of COVID19 in the western
214 Indian population (52). Unfortunately, this SNV was absent from the array used in BQC19
215 preventing the confirmation of that observation, but it is nevertheless suggestive of a link
216 between TNFSF18, kynurenine, and abnormal coagulation in severe COVID-19. Collectively, these
217 findings point to immuno-thrombosis activity in EP6 in response to SARS-CoV-2 infection that is
218 associated with abnormal coagulation. Recent results from the Antithrombotic Therapy to
219 Ameliorate Complications of COVID-19 (ATTACC) study showed anticoagulation to be efficacious
220 in moderate but not severe COVID-19 disease (53, 54), revealing a need for alternative
221 management approaches in critically ill patients.

222

223 *Novel molecular markers of COVID-19 pathology: FGFR and SHC4*

224 Two novel molecular factors associated with COVID-19 ARDS that were identified by our study
225 are FGFR and SHC4. Circulating levels of the pro-angiogenic FGF-2 has been associated with
226 COVID-19 severity and creatinine levels in a study of 208 SARS-CoV-2 positive participants (55).
227 It is also noteworthy that the use of nintedanib, an inhibitor of FGFR, vascular endothelial growth
228 factor receptor (VEGFR), and platelet-derived growth factor receptor (PDGF-R) that is approved
229 for use in interstitial lung disease, improved pulmonary inflammation and helped three middle-
230 aged obese COVID-19 patients with markedly impaired lung function wean off mechanical
231 ventilation (56). While the adaptor protein SHC4 has not been experimentally demonstrated to
232 modulate FGFR signaling, a 12-gene biomarker signature associated with melanoma contains
233 FGFR2, FGFR3 and SHC4 (57). It is attractive to speculate that SHC4 may act downstream of FGFR
234 or other associated growth factor receptors, favoring heightened procoagulant activity

235 associated with COVID-19 ARDS. In view of the limited knowledge of this understudied member
236 of the SHC family, we looked at the metabolites associated with SHC4 to gain insights into its
237 possible functions. Interestingly, 6-oxopiperidine-2-carboxylate (the only metabolite with a
238 significant correlation with SHC4 in EP6) was found to be negatively associated with glomerular
239 filtration rate in a GWAS study of kidney disease and hypertension in African Americans (58).
240 Acute kidney injury is a frequent complication of acute liver failure (59), and liver dysfunction is
241 associated with abnormal coagulation (60). Thus, the overall molecular information coming from
242 the multi-modal analysis of EP6 points to a triad between liver function, kidney function, and
243 hemostasis that becomes dysfunctional following ARDS-associated inflammation driven by SARS-
244 CoV-2 infection. Whether the presence of SHC4 in circulation is a marker of dysfunction of this
245 triad, or an active mediator, remains to be determined. Moreover, the identity of the cells
246 expressing SHC4 leading to its presence in the circulation is not known. Taken together, our
247 identification of FGFR and SHC4 signaling pathways distinguishing EP6 from other
248 endophenotypes provides a rationale for investigation of their potential utility as biomarkers of
249 severe disease activity and/or the use of antagonists of those pathways to treat severe COVID-
250 19 disease manifestations.

251

252 **Methods:**

253 **Datasets and preprocessing**

254 We obtained data corresponding to clinical, genomics, metabolomics, and proteomics
255 (circulating proteome) of n = 731 hospitalized and SARS-CoV-2 positive patients (based on qRT-
256 PCR) from the Biobanque Québécoise de la COVID-19 (BQC19; www.quebecovidbiobank.ca).

257 The circulating proteome measurements obtained using a multiplex SOMAmer affinity array
258 (SomaLogic, 4,985 aptamers) between April 2020 and April 2021 were preprocessed and used to
259 identify six endophenotypes (EP1-EP6). The details of the cohort, circulating proteome data
260 processing, and identification of endophenotypes are provided in the accompanying manuscript
261 (9).

262

263 In this study, we used the batch-normalized, missing-values-imputed, and log-transformed
264 version of the BQC19 metabolomic data (1,435 metabolites). BQC19 GWAS imputation data were
265 generated by Tomoko Nakanishi at Brent Richards lab, Jewish General Hospital and McGill
266 University. Detailed codes used for generating the data can be found in:
267 https://github.com/richardslab/BQC19_genotype_pipeline.

268

269 **Analyses of the GWAS dataset**

270 For the GWAS analyses, annotation of SNVs were done using the biomaRt package (61) from R
271 (62), and all analyses were done using R version 4.1.3. Quality control steps were derived in
272 majority from a 2017 QC tutorial article (63). At the beginning, we had 867,450 markers and 2,429
273 samples. We imported Plink format data into R using the “read_plink” function from genio R
274 package (64). We removed 103,592 non ACGT bi-allelic markers. We calculated the predicted sex
275 by looking at the rate of homozygote markers on chromosome 23. We removed 3,588 markers
276 with call rates < 98%, 448,932 monomorphic markers and markers with MAF < 0.05, and 28,092
277 markers with Hardy–Weinberg equilibrium < 1E-6 (calculated by the “HWE.exact” function from
278 the genetics package (65) from R. For the EP6 cluster group analyses, we additionally removed

279 1,747 samples that were not in the cluster analysis, 8 samples with a sex discrepancy (based on
280 predicted sex calculated earlier and reported sex), and 3 samples with a heterozygosity rate > 3
281 standard deviations. We finally removed a pair of samples which had approximately the same
282 genome, likely due to an error of manipulation. As we could not know which one was correct, we
283 removed both. We also found 2 pairs of individuals with a pi-hat of ~0.5 (meaning first degree
284 relatives), so we kept the one sample per pair with the higher call rate. All other pairs of
285 individuals had a pi-hat < 0.21 that is judged acceptable considering our population. Pi-hats were
286 calculated with the “snpGDSIBDMoM” function from SNPRelate R package (66). At the end of
287 quality controls, 283,246 markers on 655 samples had been used to perform association analyses.

288

289 To perform the principal component analyses (PCA), we took a subsample of independent
290 markers (pruning) with a maximum sliding window of 500,000 base pairs and a linkage
291 disequilibrium (LD) threshold of 0.2 using the “snpGDSLdPruning” function from the SNPRelate R
292 package. We ran the PCA with the “snpGDSPCA” function from SNPRelate package from R. The
293 first 2 principal components (PCs) were considered significant.

294

295 For the GWAS analyses of the 283,246 remaining markers between EP6 cluster compared to all
296 others, we used a logistic regression model, with the dichotomous variable indicating if the
297 participants belong to the EP6 cluster as the outcome variable. We used the additive model for
298 markers as an independent variable, and we adjusted the models with the first two PCs. Odds
299 ratio and p-values were calculated on each model. Quantile–quantile (Q–Q) plots have been
300 performed as quality control of the models; p-values were plotted using “qqplot.pvalues”

301 function from *gaston* R package (67) (data not shown). We compared the aptamers' normalized
302 level of expression between the three groups of genotypes for each studied gene by performing
303 standard analysis of variance (ANOVA) analyses followed by Tukey *post hoc* tests (referred to in
304 this study as pQTL analysis). Since aptamers tested are limited compared to SNVs, we fixed
305 significance p-value threshold below $1E-4$ to report more SNVs instead of the more common $1E-$
306 5 suggestive threshold. Finally, to identify if EP6 may be characterized by the aptamers and the
307 SNVs, we performed multiple logistic regression analysis including aptamers expression values,
308 SNV genotypes (additive model), and the two principal components. Odds ratios are reported
309 with 95% confidence intervals.

310

311 **Metabolomic pathway characterization of EP6**

312 The 1,435 metabolites measured were organized into 122 sub-pathways in the original dataset
313 (denoted as "SUB_PATHWAYS"). We first identified metabolites whose values were significantly
314 higher or lower in EP6 compared to other EPs (two-sided MWU test, $FDR < 0.01$). Then, we used
315 these metabolites to perform pathway enrichment analysis (one-sided Fisher's exact test) based
316 on 122 pathways. The resulting p-values were then corrected for multiple tests using Benjamini–
317 Hochberg FDR.

318

319 **Statistics**

320 Several non-parametric tests, including the MWU test, Fisher's exact test, and Spearman's rank
321 correlation, were used in this study. Benjamini–Hochberg FDR was used to adjust the p-values
322 for multiple tests.

323

324 **Study approval**

325 The study was approved by the Institutional Ethics Review Board of the “Centre intégré
326 universitaire de santé et de services sociaux du Saguenay-Lac-Saint-Jean” (CIUSSS-SLSJ) affiliated
327 to the Université de Sherbrooke [protocol #2021-369, 2021-014 CMDO – COVID19].

328

329 **Acknowledgements**

330 This work was made possible through open sharing of data and samples from the Biobanque
331 Québécoise de la COVID-19, funded by the Fonds de recherche du Québec - Santé, Génome
332 Québec, the Public Health Agency of Canada and, as of March 2022, the Ministère de la Santé et
333 des Services Sociaux du Québec. We thank all participants to BQC19 for their contribution. This
334 study was supported by the Fonds de recherche du Québec - Santé (FRQS)- Cardiometabolic
335 Health, Diabetes and Obesity Research Network (CMDO)- Initiative. This work was also supported
336 by Natural Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-2019-
337 04460 (AE).

338

339 **Conflict of Interests**


340 The authors have declared that no conflict of interest exists.

341


342

343

344 **Figures**




345
346 **Figure 1:** Distribution of aptamer expressions in EP6 versus other EPs.
347 The violin plots show the distribution of aptamer expressions for patients in EP6 (magenta) versus
348 EP1-5 (teal). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method
349 for adjusting the p-values were used to calculate false discovery rates.



350
351
352
353
354
355
356
357

Figure 2: Metabolite characteristics of endophenotypes (EPs).

A) The heatmap shows the enrichment (one-sided Fisher's exact test) of EPs in different metabolite sub-pathways. See Table S2 for the full list. B) The heatmap shows the over-expression (red) and under-expression (blue) of metabolites in different EPs (two-sided Mann-Whitney U test). Row names show metabolites followed by the sub-pathway to which they belong in parentheses. Only top 15 metabolites (based on false discovery rate for EP6) for which a definite name and sub-pathway was available are shown. Full list is provided in Table S2.




358

359 **Figure 3:** Distribution of metabolite levels in EP6 versus other EPs.


360 The violin plots show the distribution of metabolite levels for patients in EP6 (magenta) versus

361 EP1-5 (teal). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method


362 for adjusting the p-values were used to calculate false discovery rates.



363
364 **Figure 4:** Correlation between different variables in EP6.
365 Each circle in the scatter plots correspond to a patient in EP6. The circles are colored based on
366 the density of points surrounding them for clearer visualization. SCC corresponds to Spearman's
367 rank correlation coefficient. A) Scatter plots reflecting the correlation between metabolites (y-
368 axis) and blood variables (x-axis). B) Scatter plot corresponding to correlation of 6-oxopiperidine-
369 2-carboxylate and SHC4.



370
371 **Figure 5:** Distribution of metabolite levels in EP1 versus other EPs.
372 The violin plots show the distribution of metabolite levels for patients in EP1 (red) versus EP2-6
373 (blue). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method for
374 adjusting the p-values were used to calculate false discovery rates.
375



376
377
378
379
380
381
382
383
384
385
386
387
388

Figure 6: Mechanical ventilation in EP6.

A) The violin plots show the distribution of aptamer expressions for patients in EP6 that received mechanical ventilation (MV+) versus those that did not (MV-). Two-sided Mann–Whitney U (MWU) tests followed by Benjamini–Hochberg method for adjusting p-values were used to calculate false discovery rates. B) Distribution of age and BMI of MV+ and MV- patients in EP6. P-values are calculated using two-sided MWU tests. C) The status of sex for MV+ and MV- patients in EP6. P-value is calculated using a Fisher’s exact test. D) The scatter plot shows the correlation between expression of IDUA aptamer and number of days that patients received mechanical ventilation (n = 50).

389 **Tables**

390

391 **Table 1:** Reactome pathways associated with EP6, based on expression of aptamers. KnowEnG
392 analytical platform was used. The p-values were calculated using a one-sided Fisher's exact test
393 and were corrected for multiple tests using Benjamini–Hochberg method. Only signaling
394 pathways with FDR < 5E-4 are shown in this table (see Table S1 for the full list).

395

Pathway	FDR
Signaling by Interleukins	2.75E-12
Cytokine Signaling in Immune system	6.25E-10
Immune System	2.28E-06
Signaling by FGFR	4.75E-06
Constitutive Signaling by Aberrant PI3K in Cancer	2.94E-05
FGFR2 ligand binding and activation	5.77E-05
Extracellular matrix organization	1.85E-04
FGFR3 ligand binding and activation	1.85E-04
FGFR3c ligand binding and activation	1.85E-04
FGFRL1 modulation of FGFR1 signaling	1.85E-04
TNFs bind their physiological receptors	2.58E-04
PI3K/AKT Signaling in Cancer	3.28E-04
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4.14E-04
Interleukin-4 and 13 signaling	4.91E-04

396

397 **Table 2:** Aptamers associated with mechanical ventilation in EP6.

398 In this table, p-values are obtained using a two-sided Mann–Whitney U test and is corrected for
399 multiple tests using Benjamini–Hochberg FDR. A value of +1 (-1) in the “sign” column shows that
400 the value of aptamer was higher (lower) in the samples of 55 patients that received mechanical
401 ventilation in EP6, compared to the rest of EP6 members. Only 14 targets with FDR < 1.2E-02 are
402 shown. The full list is provided in Table S4.

403

Target	Target Full Name	p-values	FDR	Direction
GGE2D	G antigen 2D	2.93E-08	1.46E-04	+1
ANGPTL3	Angiopoietin-related protein 3	2.76E-06	4.58E-03	+1
Luteinizing hormone	Luteinizing hormone	2.55E-06	4.58E-03	-1
CRBS	Beta-crystallin S	1.01E-05	8.37E-03	-1
NCAM-120	Neural cell adhesion molecule 1; 120 kDa isoform	8.78E-06	8.37E-03	-1
SIA10	Type 2 lactosamine alpha-2;3-sialyltransferase	7.36E-06	8.37E-03	-1
LRP1	Pro-low-density lipoprotein receptor-related protein 1	2.77E-05	1.16E-02	-1
CLM2	CMRF35-like molecule 2	2.70E-05	1.16E-02	-1
THS7A	Thrombospondin type-1 domain-containing protein 7A	1.65E-05	1.16E-02	-1
LAP	Cytosol aminopeptidase	3.04E-05	1.16E-02	-1
CXCL16	C-X-C motif chemokine 16	2.64E-05	1.16E-02	+1
FSH	Follicle stimulating hormone	2.52E-05	1.16E-02	-1
VEGF sR2	Vascular endothelial growth factor receptor 2	3.27E-05	1.16E-02	-1
ASGR1	Asialoglycoprotein receptor 1	2.97E-05	1.16E-02	+1

404

405 **Table 3:** SNVs differentiating EP6 against all other endophenotype clusters.

SNV ID	Position	Gene Symbol	SNV ¹	MAF	HWE	OR ²	p-value
rs1394671	chr5:7348567	-	G > A	0.240	0.095	2.28	2.41E-06
rs12186698	chr5:168880668	<i>SLIT3</i>	T > C	0.087	0.247	2.93	3.72E-06
rs11625406	chr14:50049474	-	C > A	0.438	0.137	0.47	1.03E-05
rs11862889	chr16:83828886	-	T > C	0.104	0.446	2.62	1.07E-05
rs2995918	chr4:37905775	<i>TBC1D1</i>	C > T	0.494	0.776	0.49	1.20E-05
rs16897810	chr5:68415296	-	G > A	0.093	0.001	2.67	1.43E-05
rs2376263	chr17:35436659	<i>SLFN13</i>	G > A	0.261	0.073	2.01	2.48E-05
rs4790712	chr17:1614620	<i>SLC43A2</i>	G > A	0.441	0.003	1.97	2.50E-05
rs2294566	chr20:41472939	<i>CHD6</i>	C > A	0.239	0.265	2.04	2.78E-05
rs7164451	chr15:48921859	<i>SHC4</i>	G > A	0.386	0.053	1.89	3.01E-05
rs57664621	chr8:22808443	<i>PEBP4</i>	G > C	0.174	0.016	2.16	3.07E-05
rs28482919	chr3:14903094	<i>FGD5</i>	T > C	0.187	0.053	0.32	3.20E-05
rs6559283	chr9:89712560	-	T > C	0.375	<0.001	1.96	3.27E-05
rs657075	chr5:132094425	-	A > G	0.104	0.328	2.49	4.28E-05
rs56235109	chr15:62424001	<i>TLN2</i>	A > G	0.235	0.366	0.38	4.67E-05
rs7620057	chr3:179473377	<i>GNB4</i>	T > C	0.099	1.000	2.51	4.67E-05
rs10466868	chr12:131455375	-	T > G	0.108	0.401	2.51	5.94E-05
rs2236798	chr1:18735127	<i>PAX7</i>	A > G	0.054	0.114	2.90	6.11E-05
rs3774814	chr4:5464702	<i>STK32B</i>	C > G	0.205	<0.001	0.36	6.75E-05
rs4497815	chr19:22903215	-	G > A	0.216	0.205	2.07	7.52E-05
rs6765694	chr3:54601810	<i>CACNA2D3</i>	G > A	0.404	0.833	0.51	7.66E-05
rs2797773	chr6:37559045	-	C > T	0.422	0.000	0.53	8.06E-05
rs17014760	chr4:129419725	-	A > A	0.316	0.000	1.89	9.33E-05
rs10948260	chr6:45835559	-	G > A	0.366	0.189	1.81	9.52E-05
rs12035677	chr1:232391209	-	A > G	0.063	0.000	3.02	9.95E-05

406 Abbreviations used: SNV = Single nucleotide variation, HWE = Hardy Weinberg Equilibrium, MAF
 407 = Minor allele frequency, OR = Odd ratio.

408

409 ¹ SNV are described following GWAS annotations: refence allele > alternative allele (e.g., G > A).

410 ² Logistic regression analyses using additive model adjusted for the 2 principal components.

411

412 **Table 4:** Association between genotypes and aptamer expression levels

SNV	Gene Symbol	Nearest gene	Aptamers normalized expression ¹				Multiple logistic regression analyses ³			
			HM _{ref}	HTZ	HM _{alt}	p-val ²	Aptamers OR	p-val	SNV OR	p-val
rs6765694	<i>CACNA2D3</i>	-	-0.09 (±0.89)	0.01 (±1.10)	0.24 * (±0.99)	0.011	0.61 (0.46-0.79)	2.5E-4	0.52 (0.37-0.74)	2.4E-4
rs10948260	-	<i>CLIC5</i>	0.02 (±0.92)	0.02 (±1.09)	-0.02 (±0.97)	0.796	0.68 (0.55-0.83)	1.7E-4	1.83 (1.35-2.48)	8.8E-5
rs657075	-	<i>IL3</i>	-0.01 (±1.01)	0.05 (±0.99)	0.32 (±0.46)	0.328	1.37 (1.14-11.64)	8.2E-4	2.49 (1.60-3.88)	5.2E-5
rs7164451	<i>SHC4</i>	-	-0.07 (±0.90)	0.01 (±1.05)	0.23 * (±1.16)	0.017	11.98 (7.61-18.87)	8.4E-	2.00 (1.30-3.09)	1.8E-3
rs12186698	<i>SLIT3</i>	-	0.00 (±1.02)	0.07 (±1.06)	0.15 (±0.89)	0.509	0.82 (0.64-1.06)	0.135	2.99 (1.89-4.73)	2.7E-6
rs56235109	<i>TLN2</i>	-	-0.03 (±0.98)	0.06 (±1.03)	0.04 (±1.27)	0.353	0.58 (0.45-0.75)	2.7E-5	0.38 (0.23-0.60)	4.7E-5

413 Abbreviations used: SNV = Single nucleotide variation, HM_{ref} = Homozygotes for the reference
 414 allele, HM_{alt} = Homozygotes for the alternative allele, HTZ = Heterozygotes, OR = Odd ratio.

415
 416 ¹ Aptamers' normalized levels of expression are reported as mean (± standard deviation).
 417 Normalization steps for aptamer expressions are described in Methods.

418 ² p-value, standard ANOVA analyses followed by Tukey *post hoc* analyses. Asterisks (*) identify
 419 difference between HM_{ref} and HM_{alt} genotypes.

420 ³ Multiple logistic regression analyses models include aptamers expression values, SNV
 421 genotypes (additive model) and the two principal components. OR are reported with 95%
 422 confidence intervals in parentheses.

423

424

425 References

- 426 1. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for
427 Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* 2020; 323: 1824-1836.
- 428 2. Lim ZJ, Subramaniam A, Ponnappa Reddy M, Blecher G, Kadam U, Afroz A, et al. Case
429 Fatality Rates for Patients with COVID-19 Requiring Invasive Mechanical Ventilation. A
430 Meta-analysis. *Am J Respir Crit Care Med* 2021; 203: 54-66.
- 431 3. Berrettini WH. Genetic bases for endophenotypes in psychiatric disorders. *Dialogues Clin
432 Neurosci* 2005; 7: 95-101.
- 433 4. Froidure A, Mouthuy J, Durham SR, Chanez P, Sibille Y, Pilette C. Asthma phenotypes and
434 IgE responses. *Eur Respir J* 2016; 47: 304-19.
- 435 5. Barnes PJ. Inflammatory endotypes in COPD. *Allergy* 2019; 74: 1249-1256.
- 436 6. Koennecke M, Klimek L, Mullol J, Gevaert P, Wollenberg B. Subtyping of polyposis nasi:
437 phenotypes, endotypes and comorbidities. *Allergo J Int* 2018; 27: 56-65.
- 438 7. Baghela A, An A, Zhang P, Acton E, Gauthier J, Brunet-Ratnasingham E, et al. Predicting
439 severity in COVID-19 disease using sepsis blood gene expression signatures. *Sci Rep* 2023;
440 13: 1247.
- 441 8. LaSalle TJ, Gonye ALK, Freeman SS, Kaplonek P, Gushterova I, Kays KR, et al. Longitudinal
442 characterization of circulating neutrophils uncovers phenotypes associated with severity
443 in hospitalized COVID-19 patients. *Cell Rep Med* 2022; 3: 100779.
- 444 9. Ma W, Soulé A, Tremblay K, Rousseau S, Emad A. A circulating proteome-informed
445 prognostic model of COVID-19 disease activity that relies on routinely available clinical
446 laboratories. *medRxiv* 2022: 2022.11.02.22281834.
- 447 10. Welin A, Amirbeagi F, Christenson K, Björkman L, Björnsdottir H, Forsman H, et al. The
448 Human Neutrophil Subsets Defined by the Presence or Absence of OLFM4 Both
449 Transmigrate into Tissue In Vivo and Give Rise to Distinct NETs In Vitro. *PLOS ONE* 2013;
450 8: e69575.
- 451 11. Blatti III C, Emad A, Berry MJ, Gatzke L, Epstein M, Lanier D, et al. Knowledge-guided
452 analysis of "omics" data using the KnowEnG cloud platform. *PLoS biology* 2020; 18:
453 e3000583.
- 454 12. Gillespie M, Jassal B, Stephan R, Milacic M, Rothfels K, Senff-Ribeiro A, et al. The reactome
455 pathway knowledgebase 2022. *Nucleic Acids Research* 2021; 50: D687-D692.

- 456 13. Blachier F, Andriamihaja M, Blais A. Sulfur-Containing Amino Acids and Lipid Metabolism.
457 *The Journal of Nutrition* 2020; 150: 2524S-2531S.
- 458 14. Ye C, Sutter BM, Wang Y, Kuang Z, Tu BP. A metabolic function for phospholipid and
459 histone methylation. *Molecular cell* 2017; 66: 180-193. e8.
- 460 15. Tavoosi N, Davis-Harrison RL, Pogorelov TV, Ohkubo YZ, Arcario MJ, Clay MC, et al.
461 Molecular Determinants of Phospholipid Synergy in Blood Clotting. *Journal of Biological*
462 *Chemistry* 2011; 286: 23247-23253.
- 463 16. Parman T, Bunin DI, Ng HH, McDunn JE, Wulff JE, Wang A, et al. Toxicogenomics and
464 metabolomics of pentamethylchromanol (PMCol)-induced hepatotoxicity. *Toxicological*
465 *Sciences* 2011; 124: 487-501.
- 466 17. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, et al. Reverse signaling
467 through G1TR ligand enables dexamethasone to activate IDO in allergy. *Nature Medicine*
468 2007; 13: 579-586.
- 469 18. Marfia G, Navone S, Guarnaccia L, Campanella R, Mondoni M, Locatelli M, et al. Decreased
470 serum level of sphingosine-1-phosphate: a novel predictor of clinical severity in COVID-
471 19. *EMBO molecular medicine* 2021; 13: e13424.
- 472 19. Lone MA, Hülsmeier AJ, Saied EM, Karsai G, Arenz C, von Eckardstein A, et al. Subunit
473 composition of the mammalian serine-palmitoyltransferase defines the spectrum of
474 straight and methyl-branched long-chain bases. *Proceedings of the National Academy of*
475 *Sciences* 2020; 117: 15591-15598.
- 476 20. Han G, Gupta SD, Gable K, Niranjanakumari S, Moitra P, Eichler F, et al. Identification of
477 small subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA
478 substrate specificities. *Proceedings of the National Academy of Sciences* 2009; 106: 8186-
479 8191.
- 480 21. Chen PY, Gao WY, Liou JW, Lin CY, Wu MJ, Yen JH. Angiopoietin-Like Protein 3 (ANGPTL3)
481 Modulates Lipoprotein Metabolism and Dyslipidemia. *Int J Mol Sci* 2021; 22.
- 482 22. Lachkar F, Ferré P, Fougelle F, Papaioannou A. Dihydroceramides: their emerging
483 physiological roles and functions in cancer and metabolic diseases. *American Journal of*
484 *Physiology-Endocrinology and Metabolism* 2021; 320: E122-E130.
- 485 23. Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates
486 lipid metabolism in mice. *Nature Genetics* 2002; 30: 151-157.
- 487 24. Pisciotta L, Favari E, Magnolo L, Simonelli S, Adorni MP, Sallo R, et al. Characterization of
488 Three Kindreds With Familial Combined Hypolipidemia Caused by Loss-of-Function
489 Mutations of ANGPTL3. *Circulation: Cardiovascular Genetics* 2012; 5: 42-50.

- 490 25. Lekka ME, Liokatis S, Nathanail C, Galani V, Nakos G. The Impact of Intravenous Fat
491 Emulsion Administration in Acute Lung Injury. *American Journal of Respiratory and Critical*
492 *Care Medicine* 2004; 169: 638-644.
- 493 26. Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, et al. Inhibition of
494 Angiotensin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in
495 Hypertriglyceridemia. *Circulation* 2019; 140: 470-486.
- 496 27. Bie H, Yin J, He X, Kermode AR, Goddard-Borger ED, Withers SG, et al. Insights into
497 mucopolysaccharidosis I from the structure and action of α -L-iduronidase. *Nature*
498 *Chemical Biology* 2013; 9: 739-745.
- 499 28. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk
500 of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective
501 cohort study. *Intensive Care Medicine* 2020; 46: 1089-1098.
- 502 29. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular
503 coagulation. *International Journal of Hematology* 2021; 113: 45-57.
- 504 30. Fahmy OH, Daas FM, Salunkhe V, Petrey JL, Cosar EF, Ramirez J, et al. Is Microthrombosis
505 the Main Pathology in Coronavirus Disease 2019 Severity?-A Systematic Review of the
506 Postmortem Pathologic Findings. *Crit Care Explor* 2021; 3: e0427.
- 507 31. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al.
508 Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *Journal of*
509 *Experimental Medicine* 2020; 217.
- 510 32. Bonaventura A, Vecchié A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, et al.
511 Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-
512 19. *Nature Reviews Immunology* 2021; 21: 319-329.
- 513 33. Ding J, Hostallero DE, El Khili MR, Fonseca GJ, Milette S, Noorah N, et al. A network-
514 informed analysis of SARS-CoV-2 and hemophagocytic lymphohistiocytosis genes'
515 interactions points to Neutrophil extracellular traps as mediators of thrombosis in COVID-
516 19. *PLoS Computational Biology* 2021; 17: e1008810.
- 517 34. Blasco A, Coronado M-J, Hernández-Terciado F, Martín P, Royuela A, Ramil E, et al.
518 Assessment of neutrophil extracellular traps in coronary thrombus of a case series of
519 patients with COVID-19 and myocardial infarction. *JAMA cardiology* 2021; 6: 469-474.
- 520 35. Desilles JP, Solo Nomenjanahary M, Consoli A, Ollivier V, Faille D, Bourrienne MC, et al.
521 Impact of COVID-19 on thrombus composition and response to thrombolysis: Insights
522 from a monocentric cohort population of COVID-19 patients with acute ischemic stroke.
523 *Journal of Thrombosis and Haemostasis* 2022; 20: 919-928.

- 524 36. Englert H, Rangaswamy C, Deppermann C, Sperhake J-P, Krisp C, Schreier D, et al.
525 Defective NET clearance contributes to sustained FXII activation in COVID-19-associated
526 pulmonary thrombo-inflammation. *EBioMedicine* 2021; 67: 103382.
- 527 37. Leppkes M, Knopf J, Naschberger E, Lindemann A, Singh J, Herrmann I, et al. Vascular
528 occlusion by neutrophil extracellular traps in COVID-19. *EBioMedicine* 2020; 58: 102925.
- 529 38. Middleton EA, He X-Y, Denorme F, Campbell RA, Ng D, Salvatore SP, et al. Neutrophil
530 extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory
531 distress syndrome. *Blood* 2020; 136: 1169-1179.
- 532 39. Obermayer A, Jakob L-M, Haslbauer JD, Matter MS, Tzankov A, Stoiber W. Neutrophil
533 extracellular traps in fatal COVID-19-associated lung injury. *Disease markers* 2021; 2021.
- 534 40. Ouwendijk WJ, Raadsen MP, Van Kampen JJ, Verdijk RM, Von Der Thusen JH, Guo L, et al.
535 High levels of neutrophil extracellular traps persist in the lower respiratory tract of
536 critically ill patients with coronavirus disease 2019. *The Journal of infectious diseases*
537 2021; 223: 1512-1521.
- 538 41. Petito E, Falcinelli E, Paliani U, Cesari E, Vaudo G, Sebastiano M, et al. Association of
539 neutrophil activation, more than platelet activation, with thrombotic complications in
540 coronavirus disease 2019. *The Journal of infectious diseases* 2021; 223: 933-944.
- 541 42. Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, et al.
542 Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in
543 COVID-19 immunothrombosis. *The Journal of clinical investigation* 2020; 130: 6151-6157.
- 544 43. Massberg S, Grahl L, von Bruehl M-L, Manukyan D, Pfeiler S, Goosmann C, et al. Reciprocal
545 coupling of coagulation and innate immunity via neutrophil serine proteases. *Nature*
546 *Medicine* 2010; 16: 887-896.
- 547 44. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and
548 myeloperoxidase regulate the formation of neutrophil extracellular traps. *Journal of Cell*
549 *Biology* 2010; 191: 677-691.
- 550 45. Alder MN, Opoka AM, Lahni P, Hildeman DA, Wong HR. Olfactomedin-4 Is a Candidate
551 Marker for a Pathogenic Neutrophil Subset in Septic Shock. *Critical Care Medicine* 2017;
552 45: e426-e432.
- 553 46. Stafford JH, Thorpe PE. Increased exposure of phosphatidylethanolamine on the surface
554 of tumor vascular endothelium. *Neoplasia* 2011; 13: 299-IN2.
- 555 47. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface
556 of tumor blood vessels. *Cancer research* 2002; 62: 6132-6140.

- 557 48. Port JR, Adney DR, Schwarz B, Schulz JE, Sturdevant DE, Smith BJ, et al. High-fat high-sugar
558 diet-induced changes in the lipid metabolism are associated with mildly increased COVID-
559 19 severity and delayed recovery in the Syrian hamster. *Viruses* 2021; 13: 2506.
- 560 49. MacDonald J, Sprecher H. Distribution of arachidonic acid in choline-and ethanolamine-
561 containing phosphoglycerides in subfractionated human neutrophils. *Journal of Biological*
562 *Chemistry* 1989; 264: 17718-17726.
- 563 50. Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al. Disseminated
564 intravascular coagulation: an update on pathogenesis, diagnosis, and therapeutic
565 strategies. *Clinical and Applied Thrombosis/Hemostasis* 2018; 24: 8S-28S.
- 566 51. Lacal PM, Petrillo MG, Ruffini F, Muzi A, Bianchini R, Ronchetti S, et al. Glucocorticoid-
567 induced tumor necrosis factor receptor family-related ligand triggering upregulates
568 vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes
569 leukocyte adhesion. *J Pharmacol Exp Ther* 2013; 347: 164-72.
- 570 52. Pandit R, Singh I, Ansari A, Raval J, Patel Z, Dixit R, et al. First report on genome wide
571 association study in western Indian population reveals host genetic factors for COVID-19
572 severity and outcome. *Genomics* 2022; 114: 110399.
- 573 53. Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic
574 Anticoagulation with Heparin in Critically Ill Patients with Covid-19. *N Engl J Med* 2021;
575 385: 777-789.
- 576 54. Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic
577 Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. *N Engl J Med*
578 2021; 385: 790-802.
- 579 55. Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruet M, et al. Placental growth
580 factor level in plasma predicts COVID-19 severity and in-hospital mortality. *Journal of*
581 *Thrombosis and Haemostasis* 2021; 19: 1823-1830.
- 582 56. Bussolari C, Palumbo D, Fominsky E, Nardelli P, De Lorenzo R, Vitali G, et al. Case Report:
583 Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019. *Frontiers*
584 *in Medicine* 2021; 8: 766486.
- 585 57. Liu W, Peng Y, Tobin DJ. A new 12-gene diagnostic biomarker signature of melanoma
586 revealed by integrated microarray analysis. *PeerJ* 2013; 1: e49.
- 587 58. Luo S, Feofanova EV, Tin A, Tung S, Rhee EP, Coresh J, et al. Genome-wide association
588 study of serum metabolites in the African American Study of Kidney Disease and
589 Hypertension. *Kidney International* 2021; 100: 430-439.

- 590 59. Agarwal B, Gatt A, Riddell A, Wright G, Chowdary P, Jalan R, et al. Hemostasis in patients
591 with acute kidney injury secondary to acute liver failure. *Kidney International* 2013; 84:
592 158-163.
- 593 60. Williams R, Schalm SW, O'Grady JG. Acute liver failure: redefining the syndromes. *The*
594 *Lancet* 1993; 342: 273-275.
- 595 61. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of
596 genomic datasets with the R/Bioconductor package biomaRt. *Nature Protocols* 2009; 4:
597 1184-1191.
- 598 62. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria:
599 R Foundation for Statistical Computing; 2022. Available from: [https://www.R-](https://www.R-project.org/)
600 [project.org/](https://www.R-project.org/).
- 601 63. Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A tutorial on
602 conducting genome-wide association studies: Quality control and statistical analysis. *Int J*
603 *Methods Psychiatr Res* 2018; 27: e1608.
- 604 64. Ochoa A. *genio: Genetics Input/Output Functions*. R package version 1.1.1; 2022. Available
605 from: <https://CRAN.R-project.org/package=genio>.
- 606 65. Warnes G, Gorjanc G, Leisch F, Man M. *genetics: Population Genetics*. R package version
607 1.3.8.1.3; 2021. Available from: <https://CRAN.R-project.org/package=genetics>.
- 608 66. Zheng X, Levine D, Shen J, Gogarten SM, Laurie C, Weir BS. A high-performance computing
609 toolset for relatedness and principal component analysis of SNP data. *Bioinformatics*
610 2012; 28: 3326-3328.
- 611 67. Perdry H, Dandine-Roulland C. *gaston: Genetic Data Handling (QC, GRM, LD, PCA) &*
612 *Linear Mixed Models*. R package version 1.5.7; 2020. Available from: [https://CRAN.R-](https://CRAN.R-project.org/package=gaston)
613 [project.org/package=gaston](https://CRAN.R-project.org/package=gaston).
- 614